Read by QxMD icon Read

Weekly paclitaxel

V Guarneri, M V Dieci, G Bisagni, A Frassoldati, G V Bianchi, G L De Salvo, E Orvieto, L Urso, T Pascual, L Paré, P Galván, M Ambroggi, C A Giorgi, G Moretti, G Griguolo, R Vicini, A Prat, P F Conte
BACKGROUND: In HER2+ breast cancers, neoadjuvant trials of chemotherapy plus anti-HER2 treatment consistently showed lower pathologic complete response (pCR) rates in hormone receptor (HR) positive vs negative tumors. The PerELISA study was aimed to evaluate the efficacy of a de-escalated, chemotherapy-free neoadjuvant regimen in HR+/HER2+ breast cancer patients selected on the basis of Ki67 inhibition after 2-weeks letrozole. PATIENTS AND METHODS: PerELISA is a phase II, multicentric study for postmenopausal patients with HR+/HER2+ operable breast cancer...
February 18, 2019: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Lonny Yarmus, Christopher Mallow, Jason Akulian, Cheng Ting Lin, David Ettinger, Russell Hales, Kinh Ranh Voong, Hans Lee, David Feller-Kopman, Roy Semaan, Kirk Seward, Momen M Wahidi
BACKGROUND: Malignant airway obstruction (MAO) occurs in 30% of patients with advanced stage lung cancer leading to debilitating dyspnea, cough and hemoptysis. Other than recanalization of the airways, these patients lack long-lasting palliative therapy. The goal of this study was to determine the safety and feasibility of local injection of paclitaxel into the airway wall with a novel microinjection catheter. METHODS: In this multicentered prospective trial, 23 patients with non-small cell lung cancer (NSCLC) and MAO from July 2014 through June 2016 were enrolled to undergo rigid bronchoscopy with recanalization, followed by injection of 1...
February 15, 2019: Chest
Mahdi Aghili, Mahkameh Zare, Nima Mousavi, Reza Ghalehtaki, Sarvazad Sotoudeh, Bita Kalaghchi, Shahram Akrami, Ebrahim Esmati
Neuropathy is a dose limiting side effect of taxanes which may impact the quality of life and treatment outcomes. This randomized placebo-controlled double-blinded clinical trial was carried out to assess the efficacy of gabapentin in preventing chemotherapy induced neuropathy. Women with breast cancer were randomized into two groups of paclitaxel chemotherapy with gabapentin 300 mg/three times a day orally or placebo for 2 weeks started at day 1 of each paclitaxel cycle. Two groups were compared based on the relative frequency of neuropathy and change in nerve conducting velocity (NCV)...
February 17, 2019: Breast Journal
Mohamad Bassam Sonbol, Daniel H Ahn, David Goldstein, Takuji Okusaka, Josep Tabernero, Teresa Macarulla, Michele Reni, Chung-Pin Li, Bert O'Neil, Eric Van Cutsem, Tanios Bekaii-Saab
Napabucasin (also known as BBI-608 or BBI608) is an investigational, oral agent hypothesized to inhibit multiple oncogenic pathways. In this article, we describe the design and rationale for the CanStem111P clinical trial, a multicenter, randomized, open-label, Phase III study designed to determine the efficacy and safety of combining napabucasin with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma (NCT02993731). Patients were randomized in a 1:1 fashion to receive weekly gemcitabine and nab-paclitaxel with or without napabucasin...
February 15, 2019: Future Oncology
Toshiki Noma, Tsuyoshi Takahashi, Yasuhiro Miyazaki, Yukinori Kurokawa, Koji Tanaka, Tomoki Makino, Kiyokazu Nakajima, Makoto Yamasaki, Masaki Mori, Yuichiro Doki
A 46-year-old male patient with anorexia consulted our hospital. A scirrhous gastric cancer was found, and he was introduced to us. Laparoscopic examination was performed, and advanced peritoneal disseminated nodules were confirmed(CY1, P1). S-1 plus docetaxel therapy was introduced as first-line chemotherapy. Although the best effect judgment was PR, the primary lesion re-increased in size. We changed to the secondary weekly paclitaxel therapy. After 7 courses of the therapy, a second laparoscopic examination was performed, which confirmed the microscopic residual cancer cells(P1)in the reduced peritoneal nodules...
January 2019: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Makoto Nakai, Yutaro Hara, Shinnosuke Yonaiyama, Hiroyuki Jin, Tomohisa Tokura, Kazunori Aoki, Hiroaki Kawashima, Yoshikazu Toyoki, Masaaki Endo
A 65-year-old man was hospitalized for gastric cancer. Abdominal computed tomography detected lower gastric cancer and invasion of the liver. Initial laboratory data showed high levels of serum AFP(2,688.6 ng/mL). He underwent distal gastrectomy with left lobectomy of the liver and cholecystectomy. Histology confirmed that the tumor consisted of 2 components: primary gastric choriocarcinoma and AFP-producing carcinoma. The pathological staging was pT4b(liver), N3aM0, Stage ⅢC. After surgery, AFP levels decreased to within the normal limits...
January 2019: Gan to Kagaku Ryoho. Cancer & Chemotherapy
C N Krasner, C Castro, R T Penson, M Roche, U A Matulonis, M A Morgan, C Drescher, D K Armstrong, J K Wolfe, H Lee, J G Supko, M Seiden, M J Birrer, D S Dizon
BACKGROUND: Intraperitoneal (IP) chemotherapy can improve outcomes for women with optimally cytoreduced epithelial ovarian cancer but toxicities are a concern. We conducted 2 phase 2 trials of an IV/IP regimen using carboplatin and paclitaxel without (Trial A) and with bevacizumab (Trial B). METHODS: Both trials consisted of carboplatin AUC 6 day 1, and paclitaxel 60 mg/m2 on days 1,8, 15 of a 21-day cycle; in Trial B, patients received IV bevacizumab 15 mg/kg every cycle starting cycle 2...
February 12, 2019: Gynecologic Oncology
Ji-Young Kim, Sunyeong Lee, Yongbum Kim, Eun Ju Jeong, In-Hyun Lee, Min-Hee Son, Jae Young Lee, Sang Kyum Kim, Kyoung-Sik Moon
DHP107, an oral formulation of paclitaxel, is effectively and systemically absorbed in intestinal endothelial cells. Although the in vivo efficacy of DHP107 has been reported, the potential toxicity of DHP107 has not been evaluated. Therefore, this study was conducted to evaluate the toxicity and toxicokinetics of DHP107 orally administered to ICR mice at 25, 50, and 100 mg/kg via once-weekly dosing for six weeks. DHP107-related clinical signs were observed in both sexes at 100 mg/kg. There were significant increases in the number of platelets and percentages of reticulocytes and basophils in male mice...
February 6, 2019: Regulatory Toxicology and Pharmacology: RTP
Lynn Symonds, Hannah Linden, Vijayakrishna Gadi, Larissa Korde, Eve Rodler, Julie Gralow, Mary Redman, Kelsey Baker, Quan Vicky Wu, Isaac Jenkins, Brenda Kurland, Mitchell Garrison, Julie Smith, Jeanne Anderson, Carol Van Haelst, Jennifer Specht
INTRODUCTION: Angiogenesis and epidermal growth factor receptor signaling are potential therapeutic targets in triple negative breast cancer (TNBC). We hypothesized that targeting these critical pathways would prolong progression-free survival with first-line therapy for metastatic TNBC. PATIENTS AND METHODS: We conducted a phase II trial of nab-paclitaxel and bevacizumab, followed by maintenance therapy with bevacizumab and erlotinib, for patients with metastatic TNBC...
December 14, 2018: Clinical Breast Cancer
Alex Molassiotis, Hui Lin Cheng, Violeta Lopez, Joseph S K Au, Alexandre Chan, Aishwarya Bandla, K T Leung, Y C Li, K H Wong, Lorna K P Suen, Choi Wan Chan, Janelle Yorke, Carole Farrell, Raghav Sundar
BACKGROUND: There are inconsistencies in the literature regarding the prevalence and assessment of chemotherapy-induced peripheral neuropathy (CIPN). This study explored CIPN natural history and its characteristics in patients receiving taxane- and platinum-based chemotherapy. PATIENTS AND METHODS: Multi-country multisite prospective longitudinal observational study. Patients were assessed before commencing and three weekly during chemotherapy for up to six cycles, and at 6,9, and 12 months using clinician-based scales (NCI-CTCAE; WHO-CIPN criterion), objective assessments (cotton wool test;10 g monofilament); patient-reported outcome measures (FACT/GOG-Ntx; EORTC-CIPN20), and Nerve Conduction Studies...
February 8, 2019: BMC Cancer
C Falandry, S Gouy
In ovarian, tubal and primary peritoneal cancers, older adults have an over-mortality due to more aggressive disease (NP4), surgical and chemotherapy under treatment (NP4) and co-morbidities (NP4). Older age is at higher risk for postoperative morbidity and mortality (NP4). Surgery is more often incomplete in this elderly population (NP4). Older age is a risk factor for lower dose intensity in adjuvant chemotherapy (NP4) and incomplete chemotherapy (NP4). Nevertheless, the benefit of a complete surgery remains identical to that of the younger population (NP2)...
January 31, 2019: Gynecologie, Obstetrique, Fertilite & Senologie
David M Routman, Aurelie Garant, Scott C Lester, Courtney N Day, William S Harmsen, Cristobal T Sanheuza, Harry H Yoon, Michelle A Neben-Wittich, James A Martenson, Michael G Haddock, Christopher L Hallemeier, Kenneth W Merrell
Purpose: Grade 4 lymphopenia (G4L) during radiation therapy (RT) is associated with higher rates of distant metastasis and decreased overall survival in a number of malignancies, including esophageal cancer (EC). Through a reduction in integral radiation dose, proton RT (PRT) may reduce G4L relative to photon RT (XRT). The purpose of this study was to compare G4L in patients with EC undergoing PRT versus XRT. Methods and materials: Patients receiving curative-intent RT and concurrent chemotherapy for EC were identified...
January 2019: Advances in Radiation Oncology
Saul Eugene Rivkin, James Moon, Desiree S Iriarte, Erik Bailey, Heather L Sloan, Gary E Goodman, Amy E BonDurant, Dan Velijovich, Tanya Wahl, Peter Jiang, Chirag A Shah, Charles Drescher, Mehmet F Fer, Henry G Kaplan, Erin D Ellis
OBJECTIVE: Our goals were to: establish the maximum-tolerated dose of olaparib tablets combined with metronomic carboplatin and paclitaxel in patients with relapsed high-grade serous ovarian cancer; evaluate dose-limiting toxicities; and evaluate efficacy at the maximum tolerated dose. METHODS: In this open-label, single-arm, investigator-initiated trial ( NCT01650376), patients with high-grade serous ovarian cancer who failed primary platinum and taxane therapy received oral olaparib tablets twice daily days 1-3 each week combined with fixed-dose metronomic carboplatin AUC2 and paclitaxel 60 mg/m2 weekly for 3 out of 4 weeks...
January 29, 2019: International Journal of Gynecological Cancer
Caroline Robert, Keith Flaherty, Paul Nathan, Peter Hersey, Claus Garbe, Mohammed Milhem, Lev Demidov, Peter Mohr, Jessica C Hassel, Piotr Rutkowski, Reinhard Dummer, Jochen Utikal, Felix Kiecker, James Larkin, Anthony D'Amelio, Bijoyesh Mookerjee, Dirk Schadendorf
BACKGROUND: Primary findings from the METRIC (TMT212A2301) study demonstrated that trametinib improved progression-free survival (PFS) and overall survival (OS) compared with chemotherapy in patients with unresectable or metastatic cutaneous melanoma with a BRAF V600 E/K mutation. However, clinical data characterising the long-term use of these therapies in combination with BRAF inhibitors or as monotherapies are limited. METHODS: In this open-label, phase 3 study, 322 patients with BRAF V600 E/K-mutant metastatic melanoma were randomised in a 2:1 ratio to receive trametinib (2 mg orally, once daily; n = 214) or chemotherapy (dacarbazine [1000 mg/m2 ] or paclitaxel [175 mg/m2 ] intravenously, every 3 weeks; n = 108)...
January 25, 2019: European Journal of Cancer
Pol Specenier
Systemic treatment of metastatic melanoma has been revolutionized by the advent of checkpoint inhibitors and targeted agents which are widely accepted as standard front-line therapies. However, despite these major advances, a substantial portion of patients still fail checkpoint inhibitors and/or targeted agents and are not candidates for clinical trials. Commonly used cytotoxics in these patients include paclitaxel, dacarbazine, platins, and temozolomide. The overall response rates of these agents are usually disappointing and short-lived...
January 28, 2019: Expert Opinion on Pharmacotherapy
Jian Zhao, Meifang Yang, Xindan Wu, Zhangya Yang, Peng Jia, Yuqin Sun, Gang Li, Liang Xie, Bin Liu, Hanmin Liu
The aim of the present study was to investigate the effects of paclitaxel (PTX), at a non-cytotoxic concentration, on pulmonary vascular remodeling (PVR) in rats with pulmonary hypertension (PAH), and to explore the mechanisms underlying the PTX-mediated reversal of PVR in PAH. A total of 36 rats were divided into control group (n=12), model group (n=12) receiving a subcutaneous injection of monocrotaline (60 mg/kg) in the back on day 7 following left pneumonectomy and PTX group (n=12) with PTX (2 mg/kg) injection via the caudal vein 3 weeks following establishing the model...
February 2019: Experimental and Therapeutic Medicine
Marcelo Bonomi, Tamjeed Ahmed, Safoa Addo, Mitra Kooshki, Dario Palmieri, Beverly J Levine, Jimmy Ruiz, Stefan Grant, William J Petty, Pierre L Triozzi
The combination of standard-dose chemotherapy and immunotherapy has been shown to be beneficial for patients with non-small cell lung cancer (NSCLC) with good performance status (PS). However, treatment options for patients with poor PS are limited. In the present study, the feasibility and immunological effects of low-dose chemotherapy with carboplatin and paclitaxel combined with immunotherapy with pembrolizumab were examined in patients with metastatic NSCLC and a poor PS. Patients with advanced NSCLC and a PS of 2 were randomized to single-agent pembrolizumab at 200 mg every 3 weeks or pembrolizumab combined with weekly carboplatin area under the curve 1 and paclitaxel 25 mg/m2 ...
January 2019: Oncology Letters
Yang Liu, Zhaoguo Xu, Zhenyong Zhang, Guangfu Wen, Jiaxing Sun, Feng Han
Efficacy and safety of paclitaxel/docetaxel + epirubicin (TE), paclitaxel/docetaxel + epirubicin + cytoxan (TEC) and intensive paclitaxel (IP) neoadjuvant chemotherapy (NCT) were compared for the treatment of breast cancer. The clinical data of 326 patients with stage II-III unilateral primary breast cancer treated in Shengjing Hospital of China Medical University from January 2012 to April 2016 were retrospectively analyzed. All patients received NCT for 4 cycles, including 115 cases of TE group, 109 cases of TEC group, and 102 cases of paclitaxel weekly group...
January 2019: Oncology Letters
E Blais, V Vendrely, P Sargos, G Créhange, F Huguet, P Maingon, J-M Simon, R Bourdais, M Ozsahin, J Bourhis, K Clément-Colmou, B Belghith, M-A Proudhom Briois, O Gilliot, J-P Dujols, A Peyras, C Dupin, F-G Riet, C-H Canova, A Huertas, I Troussier
Locally advanced oesophageal cancer treatment requires a multidisciplinary approach with the combination of chemotherapy and radiotherapy for preoperative and definitive strategy. Preoperative chemoradiation improves the locoregional control and overall survival after surgery for locally advanced oesophageal cancer. Definitive chemoradiation can also be proposed for non-resectable tumours or medically inoperable patients. Besides, definitive chemoradiation is considered as an alternative option to surgery for locally advanced squamous cell carcinomas...
January 10, 2019: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
Amy S Clark, Nicholas P McAndrew, Andrea Troxel, Michael Feldman, Priti Lal, Mark Rosen, Jessica Burrell, Colleen Redlinger, Maryann Gallgher, Angela R Bradbury, Susan M Domchek, Kevin R Fox, Peter J O'Dwyer, Angela M DeMichele
PURPOSE: The CDK 4/6 inhibitor palbociclib rapidly and reversibly inhibits the cell cycle. The goal of this study was to exploit the cell cycle through intermittent, alternating dosing with palbociclib/paclitaxel to enhance efficacy. We determined the combination dose-limiting toxicity in patients with retinoblastoma (Rb) protein-expressing, advanced breast cancer (ABC). EXPERIMENTAL DESIGN: This open-label phase I trial (NCT01320592) enrolled patients to sequential cohorts of palbociclib orally dosed intermittently between days 1 and 19 of a 28 day cycle alternating with weekly paclitaxel...
January 11, 2019: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"